346 related articles for article (PubMed ID: 32327729)
1. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
Goldschmidt H; Dimopoulos MA; Rajkumar SV; Weisel KC; Moreau P; Chng WJ; Mikala G; Cavo M; Ramasamy K; Suryanarayan K; Teng Z; Labotka R; Mateos MV
Leukemia; 2020 Nov; 34(11):3019-3027. PubMed ID: 32327729
[TBL] [Abstract][Full Text] [Related]
2. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
Schjesvold F; Goldschmidt H; Maisnar V; Spicka I; Abildgaard N; Rowlings P; Cain L; Romanus D; Suryanarayan K; Rajkumar V; Odom D; Gnanasakthy A; Dimopoulos M
Eur J Haematol; 2020 May; 104(5):443-458. PubMed ID: 31880006
[TBL] [Abstract][Full Text] [Related]
3. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Dimopoulos MA; Špička I; Quach H; Oriol A; Hájek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng WJ; Leleu X; Iida S; Mateos MV; Morgan G; Vorog A; Labotka R; Wang B; Palumbo A; Lonial S;
J Clin Oncol; 2020 Dec; 38(34):4030-4041. PubMed ID: 33021870
[TBL] [Abstract][Full Text] [Related]
4. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
7. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser M; Beksaç M; Gulbrandsen N; Schjesvold F; Hájek R; Moreau P; de Arriba de la Fuente F; Mateos MV; West S; Spencer A; Rajkumar SV; Suryanarayan K; Czorniak M; Li C; Teng Z; Labotka R; Dimopoulos MA
Ann Hematol; 2020 Aug; 99(8):1793-1804. PubMed ID: 32613281
[TBL] [Abstract][Full Text] [Related]
8. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
9. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
10. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
[TBL] [Abstract][Full Text] [Related]
12. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
14. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT; Garnock-Jones KP; Scott LJ
Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis.
Chen H; Wang Y; Shao C; Sun C; Zheng C
Hematology; 2021 Dec; 26(1):1031-1039. PubMed ID: 34895096
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
18. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
